Oncology Institute, Inc.
TOINasdaq
$5.35
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↑ +65.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$544.6M
Enterprise Value
$623.2M
P/E
—
P/S
1.0
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-4.7%
Dividend Yield
—
Revenue (TTM)
$545.8M
Net Income (TTM)
$60.6B
Free Cash Flow (TTM)
-$25.7M
Gross Margin
—
Operating Margin
-6.0%
Net Margin
11107.9%
ROE
-372263.4%
ROIC
-41.4%
Debt / Equity
-4.8
Net Cash
-$78.6M
Return 1Y
+46.6%
Company profile
The Oncology Institute provides medical oncology services in the United States. Services include physician services, in-house infusion and dispensary, clinical trial services, stem cell transplants and transfusions programs. The company was founded in 2007 and is based in Cerritos, California.
- CEO
- Bradford D. Hively
- Sector
- Services
- Industry
- Healthcare
- Employees
- 660
- Headquarters
- California
- Website
- theoncologyinstitute.com
Management & directors
- Podnos YaleChief Medical Officer
- Carter Robert RossChief Financial Officer
- Virnich DanielChief Executive Officer
- England KristinChief Administrative Officer
- Langsam JeffreyChief Clinical Officer
Roles derived from SEC Form 4 filings.
Earnings
TOI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$147.4M↑ +41.2%
Diluted EPS-$0.02↓ -90.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $187.5M | $203.0M | $252.5M | $324.2M | $393.4M | $502.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.2M | -$45.9M | -$82.0M | -$77.0M | -$60.1M | -$36.1M |
| Net income | -$14.3M | -$10.9M | $152,000.00 | -$83.1M | $64.7B | $60.6B |
| Diluted EPS | -$0.24 | -$0.16 | -$0.21 | -$0.92 | -$0.71 | -$0.54 |
| Operating cash flow | $508,000.00 | -$32.7M | -$61.8M | -$36.3M | -$26.5M | -$24.6M |
| Free cash flow | -$686,000.00 | -$35.5M | -$67.3M | -$40.9M | -$30.3M | -$27.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -4.4% | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Net margin | -7.6% | -5.4% | 0.1% | -25.6% | 16436.5% | 12055.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $98.6M | $99.9M | $100.3M | $104.4M | $119.8M | $136.6M | $142.0M | $147.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.4M | -$13.9M | -$11.9M | -$9.9M | -$11.2M | -$8.1M | -$6.9M | -$6.5M |
| Net income | -$15.5M | -$16.1M | $64.7B | -$19.6M | -$17.0M | -$16.5M | $60.7B | -$2.5M |
| Diluted EPS | -$0.17 | -$0.18 | -$0.14 | -$0.21 | -$0.15 | -$0.14 | -$0.04 | -$0.02 |
| Operating cash flow | -$15.7M | $819,000.00 | $4.0M | -$5.0M | -$10.2M | -$12.6M | $3.2M | -$2.2M |
| Free cash flow | -$17.5M | $417,000.00 | $2.2M | -$5.3M | -$11.4M | -$13.2M | $2.2M | -$3.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -16.6% | -13.9% | -11.9% | -9.5% | -9.4% | -5.9% | -4.9% | -4.4% |
| Net margin | -15.7% | -16.1% | 64542.2% | -18.8% | -14.2% | -12.1% | 42730.6% | -1.7% |
Company news
Jul 16, 2026
Jul 7, 2026
- 13d agoBest Cheap Stocks Under $10 to Buy Now in Julyfinance.yahoo.com
- 13d agoThe Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidityfinance.yahoo.com
- 13d agoWhy Oncology Institute’s (TOI) Analyst Upgrades Put Its Community Cancer Care Growth Story in Focusfinance.yahoo.com
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Podnos Yale· Chief Medical Officer | Sale | 17,974 | $6.43 | $115,554.85 | filing |
| 2026-07-14 | Podnos Yale· Chief Medical Officer | Sale | 5,478 | $6.35 | $34,785.30 | filing |
| 2026-07-14 | Podnos Yale· Chief Medical Officer | Option exercise | 17,974 | $1.87 | $33,611.38 | filing |
| 2026-07-14 | Podnos Yale· Chief Medical Officer | Option exercise | 5,478 | $2.00 | $10,956.00 | filing |
| 2026-07-10 | Chernett Jorey | Buy | 15,000 | $5.85 | $87,750.00 | filing |
| 2026-07-07 | TZOUMAKAS KIMBERLY JO | Award | 17,185 | $0.00 | $0.00 | filing |
| 2026-07-07 | STOLPER MARK | Award | 25,833 | $0.00 | $0.00 | filing |
| 2026-06-23 | Chernett Jorey | Buy | 18,000 | $5.02 | $90,360.00 | filing |
| 2026-06-08 | Podnos Yale· Chief Medical Officer | Sale | 23,451 | $5.38 | $126,093.68 | filing |
| 2026-06-04 | Chernett Jorey | Buy | 12,000 | $4.75 | $57,000.00 | filing |
| 2026-05-21 | Virnich Daniel· Chief Executive Officer | J | 23,058 | $4.47 | $103,069.26 | filing |
| 2026-05-21 | Podnos Yale· Chief Medical Officer | J | 1,805 | $4.47 | $8,068.35 | filing |
| 2026-05-21 | Carter Robert Ross· Chief Financial Officer | J | 1,604 | $4.47 | $7,169.88 | filing |
| 2026-05-20 | Chernett Jorey | Buy | 33,500 | $4.07 | $136,345.00 | filing |
| 2026-05-19 | Chernett Jorey | Buy | 30,000 | $4.09 | $122,700.00 | filing |
| 2026-05-19 | Chernett Jorey | Buy | 5,000 | $4.05 | $20,250.00 | filing |
| 2026-04-16 | Kaushal Mohit | Sale | 38,433 | $3.50 | $134,534.72 | filing |
| 2026-04-14 | Kaushal Mohit | Sale | 57,286 | $3.50 | $200,598.39 | filing |
| 2026-04-09 | Chernett Jorey | Buy | 20,000 | $3.10 | $62,000.00 | filing |
| 2026-03-27 | Virnich Daniel· Chief Executive Officer | J | 98,534 | $3.07 | $302,499.38 | filing |
| 2026-03-27 | Chernett Jorey | Buy | 27,429 | $2.96 | $81,189.84 | filing |
| 2026-03-27 | Carter Robert Ross· Chief Financial Officer | J | 20,320 | $3.07 | $62,382.40 | filing |
| 2026-03-27 | Podnos Yale· Chief Medical Officer | J | 16,173 | $3.07 | $49,651.11 | filing |
| 2026-03-27 | Carter Robert Ross· Chief Financial Officer | Award | 202,914 | $0.00 | $0.00 | filing |
| 2026-03-27 | Podnos Yale· Chief Medical Officer | Award | 66,446 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.